Slide 1: Q4 & FY 2025 Earnings
Q4 & FY 2025 Earnings Earnings Presentation February 11, 2026
Slide 2: Disclaimer
Disclaimer Forward-looking statements Non-GAAP financial measures This presentation contains forward-looking statements within the meaning of Section 27A of To evaluate our performance, we monitor a number of key indicators at the consolidated the Securities Act of 1933 and Section 21E of the Securi
Slide 3: Revival will improvement across the business
Revival will improvement across the business Evolve go to Strategically invest Optimize our Simplify how Strengthen our market strategy in our manufacturing portfolio we work talent and improve and supply chain accountability organization 3
Slide 4: Q4'25 financial results
Q4’25 financial results Q4’25 Q4'24 Reported revenue $1,664M1 $1,687M Organic growth -4% 1% Adj. gross profit $524M $564M % of revenues 31.5% 33.4% Adj. EBITDA $252M1 $308M % of revenues 15.2% 18.2% Adj. operating income $225M $279M % of revenues 13.5% 16.6% Adj. earnings per share $0.22 $0.27 Free
Slide 5: FY'25 financial results
FY’25 financial results FY’25 FY'24 Reported revenue $6,552M1 $6,784M Organic growth -3% -2% Adj. gross profit $2,140M $2,291M % of revenues 32.7% 33.8% Adj. EBITDA $1,069M1 $1,199M % of revenues 16.3% 17.7% Adj. operating income $958M $1,090M % of revenues 14.6% 16.1% Adj. earnings per share $0.90
Slide 6: Q4 and FY 2025 Laboratory Solutions performance
Q4 and FY 2025 Laboratory Solutions performance Q4’25 FY’25 Reported revenue Reported revenue $1,116M $4,400M Organic growth Organic growth -4% -3% Adj. operating income Adj. operating income $114M $510M Adj. operating margin Adj. operating margin 10.2% 11.6% 6
Slide 7: Q4 and FY 2025 Bioscience Production performance
Q4 and FY 2025 Bioscience Production performance Q4’25 FY’25 Reported revenue Reported revenue $548M $2,153M Organic growth Organic growth -4% -2% Adj. operating income Adj. operating income $127M $518M Adj. operating margin Adj. operating margin 23.2% 24.1% 7
Slide 8: What is changing?
What is changing? Laboratory VWR Solutions Distribution Segment & Services Bioscience Bioscience Production & Medtech Segment Products 1. An immaterial amount of third-party fluid handling products will not be transferred into the new VWR Distribution & Services segment. 2. Proprietary lab chemicals
Slide 9: VWR Distribution & Services: Trusted partner enabling scientific insights
VWR Distribution & Services: Trusted partner enabling scientific insights Channel/Distribution: • VWR • CEC • Third-party chemicals • Other Services: Channel / Adjusted • On-site services Distribution Services Operating Income • Equipment services 2025 2025 2025 2025 Total VWR Distribution & Service
Slide 10: Bioscience & Medtech Products: Leading provider of mission-critical, high-purity materials and solutions
Bioscience & Medtech Products: Leading provider of mission-critical, high-purity materials and solutions Process Chemicals: • J.T.Baker chemicals • Other Fluid Handling: • Masterflex • Other NuSil: • Medical silicone • Industrial silicone Process Fluid Research & Adjusted Research & Specialty Chemic
Slide 11: Full year 2026 guidance
Full year 2026 guidance1 Guidance Metrics Organic revenue growth -2.5% to -0.5% Adj. EBITDA margin 14.8% to 15.3% Adj. EPS $0.77 to $0.83 Free cash flow2 $500M to $550M 1. Reported revenue range is -1.5% to 0.5%, reflecting 1% FX tailwinds. (FY blended USD / EUR exchange rate of 1.17). 2. Excludes c
Slide 12: Sharper market positioning and clarity of identity
Sharper market positioning and clarity of identity VWR Distribution & Services Bioscience & Medtech Products Channel Products Product agnostic Channel agnostic More Competitive More Accountable More Nimble 12
Slide 13: Summary
Summary • Revival is underway and we are executing with urgency • 2026 will be a year of transition and investment • We will capitalize on the equity of our powerful brands • New segments will enable faster decision-making and improved focus 13
Slide 14: Powering science at every step.
Powering science at every step. €\favantor’
Slide 15: Appendix
Appendix
Slide 16: Clinical Services divestiture impact
Clinical Services divestiture impact1,2,3 Fourth quarter impact ~$7M ~$3M Reported revenue Adjusted EBITDA headwind headwind Reported YoY Growth Adj. EBITDA Margin Headwind ~0.4% Headwind ~10bps Full year impact ~$150M ~$50M $0.03 $20M Reported revenue Adjusted EBITDA Adjusted EPS Free cash flow hea